- call +1-201-465-4211
- email sales@mrinsights.biz
Sickle Cell Disease (SCD) is a group of blood disorders typically inherited from a person's parents.
Scope of the Report:
The care of people with sickle cell disease may include infection prevention with vaccination and antibiotics, high fluid intake, folic acid supplementation and pain medication.
The global Sickle Cell Disease Treatments market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Sickle Cell Disease Treatments.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Sickle Cell Disease Treatments market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Sickle Cell Disease Treatments market by product type and applications/end industries.
Market Segment by Companies, this report covers
AstraZeneca
Eli Lilly
Bristol-Myers Squibb
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird Bio
Global Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Infection Prevention with Vaccination and Antibiotics
Blood Transfusion
The Medication Hydroxycarbamide
A Transplant of Bone Marrow Cells
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Clinics
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Sickle Cell Disease Treatments Market Overview
1.1 Product Overview and Scope of Sickle Cell Disease Treatments
1.2 Classification of Sickle Cell Disease Treatments by Types
1.2.1 Global Sickle Cell Disease Treatments Revenue Comparison by Types (2017-2023)
1.2.2 Global Sickle Cell Disease Treatments Revenue Market Share by Types in 2017
1.2.3 Infection Prevention with Vaccination and Antibiotics
1.2.4 Blood Transfusion
1.2.5 The Medication Hydroxycarbamide
1.2.6 A Transplant of Bone Marrow Cells
1.3 Global Sickle Cell Disease Treatments Market by Application
1.3.1 Global Sickle Cell Disease Treatments Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Clinics
1.3.5 Others
1.4 Global Sickle Cell Disease Treatments Market by Regions
1.4.1 Global Sickle Cell Disease Treatments Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Sickle Cell Disease Treatments Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Sickle Cell Disease Treatments Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Sickle Cell Disease Treatments Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Sickle Cell Disease Treatments Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Sickle Cell Disease Treatments Status and Prospect (2013-2023)
1.5 Global Market Size of Sickle Cell Disease Treatments (2013-2023)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 Sickle Cell Disease Treatments Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eli Lilly
2.2.1 Business Overview
2.2.2 Sickle Cell Disease Treatments Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Eli Lilly Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers Squibb
2.3.1 Business Overview
2.3.2 Sickle Cell Disease Treatments Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bristol-Myers Squibb Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis
2.4.1 Business Overview
2.4.2 Sickle Cell Disease Treatments Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 Sickle Cell Disease Treatments Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.6 Baxter
2.6.1 Business Overview
2.6.2 Sickle Cell Disease Treatments Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Baxter Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.7 Emmaus Life Sciences
2.7.1 Business Overview
2.7.2 Sickle Cell Disease Treatments Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Emmaus Life Sciences Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.8 Bluebird Bio
2.8.1 Business Overview
2.8.2 Sickle Cell Disease Treatments Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Bluebird Bio Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.9 Global Blood Therapeutics
2.9.1 Business Overview
2.9.2 Sickle Cell Disease Treatments Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Global Blood Therapeutics Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.10 Sangamo Therapeutics
2.10.1 Business Overview
2.10.2 Sickle Cell Disease Treatments Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Sangamo Therapeutics Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.11 Acceleron Pharma
2.11.1 Business Overview
2.11.2 Sickle Cell Disease Treatments Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Acceleron Pharma Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.12 Arena Pharmaceuticals
2.12.1 Business Overview
2.12.2 Sickle Cell Disease Treatments Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Arena Pharmaceuticals Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
2.13 Alnylam Pharmaceuticals
2.13.1 Business Overview
2.13.2 Sickle Cell Disease Treatments Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Alnylam Pharmaceuticals Sickle Cell Disease Treatments Revenue, Gross Margin and Market Share (2016-2017)
3 Global Sickle Cell Disease Treatments Market Competition, by Players
3.1 Global Sickle Cell Disease Treatments Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Sickle Cell Disease Treatments Players Market Share
3.2.2 Top 10 Sickle Cell Disease Treatments Players Market Share
3.3 Market Competition Trend
4 Global Sickle Cell Disease Treatments Market Size by Regions
4.1 Global Sickle Cell Disease Treatments Revenue and Market Share by Regions
4.2 North America Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
4.3 Europe Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
4.5 South America Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
5 North America Sickle Cell Disease Treatments Revenue by Countries
5.1 North America Sickle Cell Disease Treatments Revenue by Countries (2013-2018)
5.2 USA Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
5.3 Canada Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
5.4 Mexico Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
6 Europe Sickle Cell Disease Treatments Revenue by Countries
6.1 Europe Sickle Cell Disease Treatments Revenue by Countries (2013-2018)
6.2 Germany Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
6.3 UK Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
6.4 France Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
6.5 Russia Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
6.6 Italy Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Sickle Cell Disease Treatments Revenue by Countries
7.1 Asia-Pacific Sickle Cell Disease Treatments Revenue by Countries (2013-2018)
7.2 China Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
7.3 Japan Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
7.4 Korea Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
7.5 India Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
8 South America Sickle Cell Disease Treatments Revenue by Countries
8.1 South America Sickle Cell Disease Treatments Revenue by Countries (2013-2018)
8.2 Brazil Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
8.3 Argentina Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
8.4 Colombia Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Sickle Cell Disease Treatments by Countries
9.1 Middle East and Africa Sickle Cell Disease Treatments Revenue by Countries (2013-2018)
9.2 Saudi Arabia Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
9.3 UAE Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
9.4 Egypt Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
9.5 Nigeria Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
9.6 South Africa Sickle Cell Disease Treatments Revenue and Growth Rate (2013-2018)
10 Global Sickle Cell Disease Treatments Market Segment by Type
10.1 Global Sickle Cell Disease Treatments Revenue and Market Share by Type (2013-2018)
10.2 Global Sickle Cell Disease Treatments Market Forecast by Type (2018-2023)
10.3 Infection Prevention with Vaccination and Antibiotics Revenue Growth Rate (2013-2023)
10.4 Blood Transfusion Revenue Growth Rate (2013-2023)
10.5 The Medication Hydroxycarbamide Revenue Growth Rate (2013-2023)
10.6 A Transplant of Bone Marrow Cells Revenue Growth Rate (2013-2023)
11 Global Sickle Cell Disease Treatments Market Segment by Application
11.1 Global Sickle Cell Disease Treatments Revenue Market Share by Application (2013-2018)
11.2 Sickle Cell Disease Treatments Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.5 Clinics Revenue Growth (2013-2018)
11.6 Others Revenue Growth (2013-2018)
12 Global Sickle Cell Disease Treatments Market Size Forecast (2018-2023)
12.1 Global Sickle Cell Disease Treatments Market Size Forecast (2018-2023)
12.2 Global Sickle Cell Disease Treatments Market Forecast by Regions (2018-2023)
12.3 North America Sickle Cell Disease Treatments Revenue Market Forecast (2018-2023)
12.4 Europe Sickle Cell Disease Treatments Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Sickle Cell Disease Treatments Revenue Market Forecast (2018-2023)
12.6 South America Sickle Cell Disease Treatments Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Sickle Cell Disease Treatments Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Sickle Cell Disease Treatments Picture
Table Product Specifications of Sickle Cell Disease Treatments
Table Global Sickle Cell Disease Treatments and Revenue (Millio
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
